[go: up one dir, main page]

AU2003260723A1 - Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer - Google Patents

Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer

Info

Publication number
AU2003260723A1
AU2003260723A1 AU2003260723A AU2003260723A AU2003260723A1 AU 2003260723 A1 AU2003260723 A1 AU 2003260723A1 AU 2003260723 A AU2003260723 A AU 2003260723A AU 2003260723 A AU2003260723 A AU 2003260723A AU 2003260723 A1 AU2003260723 A1 AU 2003260723A1
Authority
AU
Australia
Prior art keywords
ephitoline
alkaloyds
eleutherobine
cryptophycine
taxane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003260723A
Inventor
Lawrence R. Mcgrath
Stephen P. Mcilroy
Peter A. Passmore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University of Belfast
Original Assignee
Queens University of Belfast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0219241A external-priority patent/GB0219241D0/en
Priority claimed from GBGB0225206.2A external-priority patent/GB0225206D0/en
Application filed by Queens University of Belfast filed Critical Queens University of Belfast
Publication of AU2003260723A1 publication Critical patent/AU2003260723A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003260723A 2002-08-17 2003-08-18 Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer Abandoned AU2003260723A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0219241A GB0219241D0 (en) 2002-08-17 2002-08-17 Medicaments
GBGB0219241.7 2002-08-17
GBGB0225206.2 2002-10-30
GBGB0225206.2A GB0225206D0 (en) 2002-10-30 2002-10-30 Medicaments
PCT/GB2003/003601 WO2004016269A1 (en) 2002-08-17 2003-08-18 Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer

Publications (1)

Publication Number Publication Date
AU2003260723A1 true AU2003260723A1 (en) 2004-03-03

Family

ID=31889682

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003260723A Abandoned AU2003260723A1 (en) 2002-08-17 2003-08-18 Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer

Country Status (2)

Country Link
AU (1) AU2003260723A1 (en)
WO (1) WO2004016269A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DK1767535T3 (en) 2002-08-23 2010-04-12 Sloan Kettering Inst Cancer Synthesis of epothilones, their intermediates, analogs and their use
CN104116736A (en) 2008-04-24 2014-10-29 百时美施贵宝公司 Use of epothilone D in treating Tau-associated diseases including Alzheimer's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0870510A3 (en) * 1997-04-11 1999-09-15 Eli Lilly And Company Synergistic combination comprising cryptophycin derivatives and microtubule synergizing agents

Also Published As

Publication number Publication date
WO2004016269A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
AU2003237159A1 (en) Treatment for phenylketonuria
AU2002319538A1 (en) Organic slurry treatment process
AU2003249244A1 (en) Methods for the treatment of neoplasms
AU2003212634A1 (en) Compounds useful in the treatment of cancer
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
EP1551388A4 (en) Compounds useful for the treatment of cancer, compositions thereof and methods therewith
AU2003903242A0 (en) Process for the treatment of wood
AU2003222022A1 (en) Methods for treating deodorizer distillate
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
AU2003223538A1 (en) Methods for the treatment of cancer
EP1575497A4 (en) Novel composition and methods for the treatment of psoriasis
AU2003291886A1 (en) Thiophenederivatives for the treatment of flavivirus infections
AU2003260723A1 (en) Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer
AU2003258983A1 (en) Combinations for the treatment of fungal infections
AU2003224486A1 (en) Composition for treating cancer containing n,n-dimethylphytosphingosine
AU2003205452A1 (en) Bmp inhibitors for the treatment of spondyloarthropathies
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2003281836A1 (en) Implant for the treatment of presbyopia
AU2003289889A1 (en) Methods for the treatment of alzheimers disease and compositions therefore
AU2003249999A1 (en) 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours
AU2003274067A1 (en) Compounds for the treatment of cough
AU2003212888A1 (en) Combinations for the treatment of fungal infections

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase